The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)
The National Comprehensive Cancer Network (NCCN) is a national panel of experts that creates guidelines for cancer treatment. For women who have had a complete or partial response to fist-line therapy, the NCCN recommends the following:
NCT03522246: A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA). ATHENA is a study for women who are newly diagnosed with ovarian cancer. The goal of ATHENA is to look at whether giving maintenance therapy with different agents improves outcomes for women who have completed front-line treatment.
NCT02855944. ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients. ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.